Predictive Immune Modeling News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cofactor Genomics Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients

Cofactor Genomics Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jarret glasscockNature publishing groupJournal of cancer researchCancer researchClinical oncologyPredictive immune modeling

Cofactor Genomics Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients

Cofactor Genomics Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients
venturebeat.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from venturebeat.com Daily Mail and Mail on Sunday newspapers.

Jarret glasscockNature publishing groupJournal of cancer researchCancer researchClinical oncologyPredictive immune modeling

Cofactor Genomics unveils new data demonstrating novel OncoPrism diagnostics

Cofactor Genomics, a predictive immune modeling company, today presented initial results from the multi-center clinical study PREDAPT (Predicting

Precision healthTechnology precision health meetingCofactor genomicsPre treatment tumor biopsiesGenome biologyTechnology precision healthPredictive immune modeling

Reportable, Inc : Cofactor Genomics Commences First Predictive Immune Modeling Clinical Trial to Bridge Precision Medicine Gap for Immunotherapy

(0) San Francisco, California (Newsfile Corp. - April 13, 2021) - Cofactor Genomics, the company bridging the precision medicine gap, today announced commencement of the first multicenter clinical trial of its OncoPrismTM diagnostic assay, using the company s patented approach to generating multidimensional immune biomarkers. Fifteen hospitals and healthcare networks, including Mayo Clinic, MultiCare Institute for Research and Innovation, and Revive Research Institute, are currently enrolling in the PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) Trial to evaluate use of the OncoPrism test in patients with recurrent and metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) to effectively predict a patient s response to immunotherapy. The company expects additional sites to join the trial before the end of 2021.

San franciscoUnited statesMariesa kembleKostenloser wertpapierhandelHealth expression modelsResearch instituteCalifornia newsfile corpChronic communications incMulticare institute for researchMayo clinicRevive research institutePre treatment tumor biopsiesCofactor genomicsPredictive immune modelingPrecision medicine gapPredictive immune